Breber Pierre R

Director Breber buys 5,000 CLX shares at open market; stock trading well below 52-week highs amid recent weakness.

Director Pierre R Breber purchased over 5,000 shares of Clorox at the open market, representing a meaningful addition to his position. The timing is notable: the stock has pulled back significantly from its highs and is currently near the lower bound of its recent range, suggesting Breber is buying into weakness rather than chasing momentum. Clorox remains a profitable company with solid fundamentals and a reasonable valuation multiple, making this the type of backdrop where insider buying can signal genuine conviction. As a director with board-level insight into the company's strategy and operations, Breber's willingness to deploy capital here—particularly after a sharp recent decline—indicates he may view the current price as attractive relative to long-term value. This type of buying by a company insider during a pullback merits monitoring as a potential contrarian signal.

Director Pierre Breber buys 4,000 CLX shares at $104.13, increasing holdings by 44.4% to 13,000 shares

Director Pierre Breber purchased 4,000 shares of Clorox at $104.13 on 2025-11-21, representing a substantial 44.4% increase in his holdings. The transaction occurred when the stock was trading 37.8% below its 52-week high and down 8.8% over the prior 30 days. However, his prior buy at this ticker on 2025-05-07 did not result in a well-timed entry, with negative 90-day and 30-day returns, indicating that timing accuracy at Clorox specifically has not been reliable despite his strong 95.00% 90-day win rate across his broader cross-ticker trading activity. The company's fundamentals show modest revenue of $1.4B with net income of $80.0M and annual revenue growth of only +0.2%, reflecting a mature business with limited organic growth momentum.

Director Breber Pierre R buys 4,000 CLX shares at $136.57; first position (0→4.0K shares); stock at -20.6% from 52-week high.

Breber's purchase of 4,000 shares at $136.57 on 2025-05-07 establishes an initial position in Clorox after no prior holdings, representing a new director-level commitment to the company. The transaction occurs while CLX trades -20.6% from its 52-week high of $169.74 and -9.2% over 90 days, placing the purchase in a period of relative weakness. His cross-ticker track record shows 20 prior buys across his open-market history, indicating a pattern of accumulating positions rather than net selling activity. However, the stock's fundamentals show annual revenue declining 4.0% and a P/E of 23.94, with the company generating $186.0M net income on $1.7B quarterly revenue, warranting close attention to execution and near-term guidance.

Director Breber Pierre R purchased 5,000 shares of PCAR at $89.78 on 2025-05-06, expanding holdings by 62.4% to 13,015 shares.

Director Breber Pierre R acquired 5,000 shares worth $448,900.00 at $89.78, a transaction that represents a substantial 62.4% increase in his position holdings. The purchase occurred when PCAR's stock was trading -25.1% below its 52-week high of $118.41, following a -17.6% decline over the prior 90 days. The director's cross-ticker track record shows 20 prior open-market buys, indicating a consistent pattern of equity purchases across his portfolio. PCAR itself trades at a P/E of 13.42 with annual revenue declining -4.2% year-over-year, though the company posted net income of $505,100,000.00 in its latest quarter from revenue of $7,441,700,000.00.

Director Breber Pierre R purchased 10,000 shares of LUV at blended avg $26.89; 19 transactions totaling $268.9K, expanding stake to 44.0K shares (+29.4%)

Breber Pierre R executed 19 separate open-market purchases on 2025-04-29 totaling 10,000 shares for $268,876.97 at prices ranging from $26.74 to $27.00, raising his holdings from 34,000 to 44,000 shares. The stock is currently trading at $27.96, down -19.8% from its 52-week high and -16.7% over the past 30 days. A cluster of 2 other insiders also bought within the past 14 days, forming a coordinated buying pattern. His cross-ticker track record shows 1 prior sell with a well-timed rate of 100.00%, indicating his past open-market sales preceded subsequent declines. Southwest's recent fundamentals show a net loss of $149.0M in the latest quarter, though annual revenue grew +5.3%. The multi-transaction structure and scale of this purchase—representing a 29.4% increase in his holdings—warrants investor attention against the backdrop of the stock's downward price momentum and the broader cluster activity.